Gefticip Tablet
Marketer
Cipla Ltd
Salt Composition
Gefitinib (250mg)
Overview Gefticip Tablet
Erlotinib tablets are indicated for advanced non-small cell lung carcinoma. This medication is prescribed for patients with metastatic disease, possessing abnormal epidermal growth factor receptor (EGFR) genes, and without prior cancer therapy. Dosage should strictly adhere to your physician's instructions, continuing treatment for the prescribed duration, which is individualized based on response and clinical need. Regular liver function monitoring may be recommended. Frequently reported adverse reactions include nausea, diarrhea, dry skin, and decreased appetite. Increased fluid intake may mitigate these effects. Report any persistent or worsening side effects to your doctor immediately. Seek immediate medical attention if you experience oral ulceration, visual disturbances, or respiratory distress. Effective contraception is crucial during treatment and for one month post-treatment. Complete disclosure of all current medications to your prescribing physician is essential.
Uses of Gefticip Tablet
Lung cancer (excluding small cell types)
Major Benefits of Gefticip Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Gefticip Tablets can be consumed with or without food, though consistent timing is recommended.
Common Side effects of Gefticip Tablet:
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Vomiting
- Weakness
- Weight loss
- Eating disorder
- Allergic reaction
How to use Gefticip Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Gefticip Tablets can be taken with or without food; however, consistent daily timing is recommended.
How Gefticip Tablet works:
Gefticip tablets are an anticancer drug that inhibits the activity of a faulty protein responsible for triggering cancer cell proliferation, thus hindering or retarding cancerous growth.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol alongside Gefticip Tablet is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Gefticip Tablet during pregnancy poses a known risk to the fetus. Therefore, it's contraindicated, except in rare, life-threatening circumstances where a physician deems the potential benefits outweigh the hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Using Gefticip tablets while breastfeeding is likely inadvisable. Preliminary human research indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Driving ability may be impaired by side effects associated with Gefticip Tablet.
KidneyCAUTION
Patients with severe kidney impairment should use Gefticip Tablet cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
Patients with liver disease can likely use Gefticip Tablet safely. Existing evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
What if you forget to take Gefticip Tablet :
Omit any missed Gefticip Tablet dose; resume your regular dosing regimen. Avoid taking a double dose.
Facts to Know About Gefticip Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline amines |
| Developing Habits | No. |
| Treatment Category | Cancer Therapeutics |
3,018 People bought this recently